Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer

Prostate

Volumn 72, Issue 7, 2012, Pages 741-751

  Kashiwagi, Eiji ^a   Shiota, Masaki ^a   Yokomizo, Akira ^a   Itsumi, Momoe ^a   Inokuchi, Junichi ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CRPC; oxidative stress; PDE4B; PKA; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; HYDROGEN PEROXIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVB; ROLIPRAM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; HYDROGEN PEROXIDE; ISOQUINOLINES; MALE; PHOSPHODIESTERASE 4 INHIBITORS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; ROLIPRAM; SULFONAMIDES;

EID: 84860320134     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21478     Document Type: Article

References (45)

1. Garzotto M, Myrthue A, Higano CS, Beer TM,. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006; 24: 254-259.
2. Kung HJ, Evans CP,. Oncogenic activation of androgen receptor. Urol Oncol 2009; 27 (1): 48-52.
3. Kim J, Jia L, Stallcup M, Coetzee G,. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 2005; 34 (1): 107-118. (Pubitemid 40305553)
4. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JMS, Edwards J,. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007; 97 (3): 378-383. (Pubitemid 47196744)
5. Ueda T, Bruchovsky N, Sadar MD,. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277 (9): 7076-7085. (Pubitemid 34959964)
6. Wang G, Jones S, Marra M, Sadar M,. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene 2006; 25 (55): 7311-7323. (Pubitemid 44809097)
7. Merkle D, Hoffmann R,. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 2011; 23 (3): 507-515.
8. Bradbury A, Carter D, Miller W, Cho-Chung Y, Clair T,. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994; 69 (4): 738-742. (Pubitemid 24112697)
9. Miller W, Hulme M, Cho-Chung Y, Elton R,. Types of cyclic AMP binding proteins in human breast cancers. Eur J Cancer 1993; 29 (7): 989-991. (Pubitemid 23126697)
10. Khor L, Bae K, Al-Saleem T, Hammond E, Grignon D, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A,. Protein kinase A RI-[alpha] predicts for prostate cancer outcome: Analysis of Radiation Therapy Oncology Group Trial 86-10. Int J Radiat Oncol Biol Phys 2008; 71 (5): 1309-1315.
11. James MA, Lu Y, Liu Y, Vikis HG, You M,. RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 2009; 69 (5): 2108-2116.
12. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y,. Androgen receptor activation by Gs signaling in prostate cancer cells. J Biol Chem 2005; 280 (12): 11583-11589. (Pubitemid 40418471)
13. Xie Y, Wolff DW, Lin MF, Tu Y,. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol Pharmacol 2007; 72 (1): 73-85. (Pubitemid 46998526)
14. Sadar M,. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999; 274 (12): 7777-7783.
15. Bagchi G, Wu J, French J, Kim J, Moniri NH, Daaka Y,. Androgens transduce the Gαs-mediated activation of protein kinase A in prostate cells. Cancer Res 2008; 68 (9): 3225-3231.
16. Ckert S, Oelke M, Stief C, Andersson K, Jonas U, Hedlund P,. Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49 (4): 740-745. (Pubitemid 43374744)
17. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S,. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29 (2): 237-250.
18. Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, Arao T, Nishio K, Naito S, Kohno K,. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Science 2011; 102 (2): 382-386.
19. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S, Kohno K,. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68 (1): 98-105. (Pubitemid 351380110)
20. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y,. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69 (7): 3148-3156.
21. Nesterova MV, Cho-Chung YS,. Significance of protein kinase A in cancer. Apoptosis Cell Signaling Hum Dis 2007; 1: 3-30.
22. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45. (Pubitemid 33741879)
23. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J,. Androgen receptor phosphorylation. J Biol Chem 2002; 277 (32): 29304-29314.
24. Nazareth L, Weigel N,. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996; 271 (33): 19900-19907. (Pubitemid 26281734)
25. Mosch HU, Kubler E, Krappmann S, Fink GR, Braus GH,. Crosstalk between the Ras2p-controlled mitogen-activated protein kinase and cAMP pathways during invasive growth of Saccharomyces cerevisiae. Mol Biol Cell 1999; 10 (5): 1325-1335. (Pubitemid 29230893)
26. Choi JH, Choi KC, Auersperg N, Leung PCK,. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66 (7): 3912-3920.
27. Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Cook LM, Diers AR, Landar A, Welch DR,. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Res 2010; 70 (23): 10002-10011.
28. Houslay MD,. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001; 69: 249-315. (Pubitemid 33805840)
29. Houslay MD, Adams DR,. PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370 (Pt 1): 1-18. (Pubitemid 36259414)
30. Houslay MD, Schafer P, Zhang KYJ,. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10 (22): 1503-1519. (Pubitemid 41527193)
31. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RCT,. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105 (1): 308-316. (Pubitemid 40053098)
32. Marko D, Pahlke G, Merz KH, Eisenbrand G,. Cyclic 3',5'-nucleotide phosphodiesterases: Potential targets for anticancer therapy. Chem Res Toxicol 2000; 13 (10): 944-948.
33. Narita M, Murata T, Shimizu K, Nakagawa T, Sugiyama T, Inui M, Hiramoto K, Tagawa T,. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Oncol Rep 2007; 17 (5): 1133-1139.
34. Goldhoff P, Warrington NM, Limbrick DD, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB,. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 2008; 14 (23): 7717-7725.
35. Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M,. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 2009; 69 (10): 4388-4396.
36. Moon EY, Lerner A,. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003; 101 (10): 4122-4130. (Pubitemid 36857894)
37. Ogawa R, Streiff M, Bugayenko A, Kato G,. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21 (WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 2002; 99 (9): 3390-3397. (Pubitemid 34525321)
38. Amorino GP, Parsons SJ,. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004; 14 (4): 287-300. (Pubitemid 40221058)
39. Bang Y, Pirnia F, Fang W, Kang W, Sartor O, Whitesell L, Ha M, Tsokos M, Sheahan M, Nguyen P,. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994; 91 (12): 5330-5334. (Pubitemid 24174320)
40. Cox ME, Deeble PD, Lakhani S, Parsons SJ,. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible. Cancer Res 1999; 59 (15): 3821-3830.
41. Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA,. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 2007; 19 (2): 401-409. (Pubitemid 46017085)
42. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK,. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68 (6): 1777-1785. (Pubitemid 351416563)
43. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, Breemen R, Ashton D, Bowen PE,. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. JNCI J Natl Cancer Inst 2001; 93 (24): 1872-1879. (Pubitemid 34048654)
44. McCord J,. Superoxide radical: Controversies, contradictions, and paradoxes. Proc Soc Exp Biol 1995; 209 (2): 112-117.
45. Martin K, Barrett J,. Reactive oxygen species as double-edged swords in cellular processes: Low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol 2002; 21 (2): 71-75. (Pubitemid 34591267)